Sergio Giralt
YOU?
Author Swipe
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Supplementary Data1 from Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation
Supplementary Data1 from Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation Open
Supplementary Data
View article: Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort Open
View article: Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Purpose:Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transpla…
View article: Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation
Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation Open
Introduction: High-dose melphalan followed by autologous stem cell transplantation (HDM/ASCT) remains a cornerstone of multiple myeloma (MM) therapy. While safe and effective, HDM/ASCT involves a substantial increase in short-term healthca…
View article: Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study
Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study Open
Introduction: The risk of second primary malignancies (SPMs) has emerged as a growing clinical concern in patients with multiple myeloma (MM) who currently achieve prolonged survival. The reported cumulative incidence of SPMs in MM has var…
View article: Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Trial protocol
View article: Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Revised supplement
View article: Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide
Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide Open
Background: Fludarabine (Flu) is a key conditioning agent to induce host lymphopenia and prevent rejection prior to allogeneic hematopoietic cell transplantation (alloHCT). Immunosuppression from Flu may increase non-relapse mortality (NRM…
View article: Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma Open
View article: Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel Open
Non-ICANS neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel, a commercial chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory multiple myeloma. Risk factors contr…
View article: Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: SUN-304 Associations of BMI Changes and Adipokines with Survival and Treatment Response During Myeloma Induction Therapy
SUN-304 Associations of BMI Changes and Adipokines with Survival and Treatment Response During Myeloma Induction Therapy Open
Disclosure: R. Thirugnanasambandam: None. R. Firestoe: None. A. Derkach: None. T. Shekarkhand: None. C. Rueda: None. K. Maclachlan: None. M.L. Hultcrantz: None. S. Mailankody: None. D. Patel: None. H. Landau: None. G. Shah: None. M. Scordo…
View article: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies Open
View article: Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience
Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience Open
View article: Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant Open
The bone marrow represents the tumor microenvironment for many hematologic malignancies and a potentially critical site for alloimmunity after hematopoietic transplantation. Despite the importance of immune reconstitution (IR) after transp…
View article: Post-Transplant Pain and Paralysis: Neurologic Amyotrophy as an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant
Post-Transplant Pain and Paralysis: Neurologic Amyotrophy as an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant Open
Background: Neuralgic amyotrophy (NA), also known as Parsonage–Turner syndrome, brachial neuritis, and idiopathic brachial plexopathy, is a rare and potentially debilitating peripheral nerve disorder characterized by acute-onset shoulder p…
View article: Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation Open
Double-unit cord blood transplantation (dCBT) has been associated with high rates of progression-free survival (PFS) in adults with hematologic malignancies but also with relatively high rates of acute graft-versus-host disease (aGVHD). We…
View article: Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma Open
Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center…
View article: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience Open
View article: Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma Open
Patients with peripheral T-cell lymphoma (PTCL) have suboptimal outcomes. Autologous hematopoietic stem-cell transplantation (AHCT) is a therapeutic strategy for patients in first complete remission (CR1) or first partial remission (PR1), …
View article: An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma Open
View article: Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing Open
View article: Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies Open
Despite clinical benefit with the use of chimeric antigen receptor (CAR) T cells, the need to manufacture patient-specific products limits its clinical utility. To overcome this barrier, we developed an allogeneic “off-the-shelf” CAR T-cel…
View article: CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i> Open
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral…
View article: Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy Open
Chimeric Antigen Receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatmentrelated toxicity. Cytokine release syndrome and immu…
View article: Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Figure S2 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Figure S2. Patterns of first failure for RT bridged patients.
View article: Supplementary Table S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Supplementary Table S1 from Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma Open
Supplementary Table S1. Systemic bridging regimens.